Clover Health Investments, Corp. /de (CLOV) · Nov 4, 2026 · Earnings
Beat — GAAP EPS $0.01 vs ~$0.00 consensus; revenue $759.3M vs ~$740.1M
Clover Health earnings beat Q3 revenue and EPS expectations, while higher guidance reinforces its shift toward sustainable Medicare Advantage profitability.
Clover is scaling a technology-enabled Medicare Advantage insurer around Clover Assistant, with the investment case shifting from survival and growth toward proving that larger member cohorts can produce durable profits. Before this release, management had already raised 2026 guidance after a strong second quarter, while published Q3 expectations were roughly breakeven EPS and $740 million of revenue.
The quarter beat a low bar, but it was a real beat. Revenue reached $759.3 million, about 2.6% above the approximately $740.1 million consensus, while GAAP net income was $6.4 million versus an expectation around breakeven. The more important operating evidence was the 240-basis-point improvement in the Insurance BER to 91.1%, showing that medical-cost performance improved even as membership expanded 46.3% year over year. (Financial Highlights; Insurance Benefits Expense Ratio)
| Metric | Q3 2026 | Q3 2025 | Consensus / Prior guidance |
|---|---|---|---|
| Total revenues (Financial Highlights) | $759.3M (+52.9%) | $496.7M | ~$740.1M |
| GAAP net income (Income Statement) | $6.4M | $(24.4M) | ~$(2.7M) |
| Adjusted EBITDA (Financial Highlights) | $16.1M (+666.7%) | $2.1M | |
| Insurance BER (Financial Highlights) | 91.1% (-240 bps) | 93.5% | |
| FY26 revenue guidance (Guidance table) | $2.97B-$3.00B | $2.92B-$3.00B | |
| FY26 GAAP net income guidance (Guidance table) | $25M-$35M | $20M-$35M | |
| FY26 Adjusted EBITDA guidance (Guidance table) | $75M-$85M | $70M-$85M |
Guidance improved, but mainly by lifting the floor. Clover raised the low end of revenue, GAAP net income, gross profit, Adjusted EBITDA, and average membership guidance, while leaving every upper bound unchanged. That is a constructive confirmation of execution, not a wholesale reset of the 2026 outlook. Management said it expects “its first full year of GAAP Net Income profitability,” reinforcing that the profitability transition remains the central business milestone.
The underlying story is strengthening, but this filing does not rewrite it. Membership growth, improving claims performance, and positive cash generation support the existing thesis that maturing cohorts can expand margins. Yet adjusted SG&A as a percentage of revenue rose sequentially to 15.0% from 14.3% a year earlier, and the guidance change is modest because the top ends did not move. The result therefore advances Clover's current plan rather than proving a fundamentally new business model.
Bottom line: Clover delivered a modest earnings beat and slightly better 2026 guardrails. It strengthens the profitability transition already underway, but the limited guidance lift makes this an incremental positive rather than a story-changing quarter.
Q4 and full-year 2026 results, early 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!